国际皮肤性病学杂志    2002 28 (6): 337-339   ISSN: 2096-5540  CN: 32-1880/R   限局性银屑病的外用治疗 楚瑞琦1, 刘平2, 谭升顺2, 彭振辉2 1. 河北省职工医学院附属医院皮肤科; 2. 西安交通大学第二医院皮肤科, 710004 收稿日期 2002-01-14  修回日期 null  网络版发布日期 null 参考文献  [1] Smith CH, Jackson K, Chinn S, et al. A double blind, randomized,controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis. Clin Exp Dermatol, 2000, 25(8):580-583. [2] Prins M, Swinkels OQ, Bouwhuis S, et al. Dithranol in a cream preparation:disperse or dissolve? Skin Pharmacol Appl Skin Physiol,2000, 13(5):273-279. [3] Prins M, Swinkels OQ, Van de Kerkhof PC, et al. The impact of the frequency of short contact dithranol treatment. Eur J Dermatol, 2001,11(3):214-218. [4] Yamamoto T, Matsuuchi M, Irimajiri J, et al. Topical anthralin for psoriasis vulgaris:evaluation of 70 Japanese patients. J Dermatol,2000, 27(7):482-485. [5] Swinkels OQ, Prins M, Tosserams EF, et al. The influence of a topical corticosteroid on short-contact high-dose dithranol therapy. Br J Dermatol, 2001, 145(1):63-69. [6] Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 &mgr;g/g ointment in the treatment of plaque psoriasis:a comparison with short-contact dithranol. Dermatology, 2000, 201(2):139-145. [7] Carrozza P, Hausermann P, Nestle FO, et al. Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study. Dermatology, 2000,200(1):35-39. [8] Muller K, Breu K, Reindl H. 10-Phenylbutyryl-substituted anthracenones as inhibitors of keratinocyte growth and LTB (4) biosynthesis.Eur J Med Chem, 2001, 36(2):179-184. [9] Muller K, Reindl H, Breu K. Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation. Bioorg Med Chem Lett, 2001, 11 (1):47-50. [10] Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol, 2000, 80(6):451. [11] Sutton L, Swinehart JM, Cato A, et al. A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int J Dermatol,2001,40(7):464-467. [12] Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate:iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm, 2001,215(1-2):57-65. [13] Queille-Roussel C, Duteil L, Parneix-Spake A,et al. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur J Dermatol, 2001, 11 (3):219-224. [14] Schlotmann K, Ortland C, Neumann NJ, et al. Placebo-controlled evaluation of the irritant potential of tacalcitol (la,24-dihydroxyvitamin D3) in healthy volunteers. Contact Dermatitis, 2000, 42 (5):260-263. [15] Nakayama J. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1 a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol, 2000, 10 (7):528-532. [16] Messer G, Degitz K, Plewig G,et al. Pretreatment of psoriasis with the vitamin D3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B:results of a controlled, right/left study. Br J Dermatol, 2001, 144(3):628-629. [17] Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol, 2000, 43(2 Pt 3):S31-S35. [18] Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis, 2000, 66(6 Suppl):4-11. [19] Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol, 2000, 43(5 Pt 1):821-828. [20] Schiener R, Behrens-Williams SC, Pillekamp H, et al. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B(311 nm):efficacy in patients with severe psoriasis. Br J Dermatol,2000, 143(6):1275-1278. 通讯作者: